ABSTRACT
Buspirone, a partial agonist of 5-hydroxytryptaminelA autoreceptors, preferentially blocks the presynaptic rather than the postsynaptic D2 dopamine (DA) receptors. Behavioural effects of a wide dose range of buspirone were therefore studied in mice. Buspirone at 0.625 to 5 mg/kg ip induced stereotyped cage climbing behaviour which was antagonized by pretreatment with haloperidol, alpha-methyl-p-tyrosine and small doses of apomorphine. Buspirone at 10, 20 and 40 mg/kg ip induced catalepsy and antagonized oral stereotypies induced by high doses of apomorphine and methamphetamine and apomorphine-induced cage climbing behaviour. The findings indicate that buspirone at 0.625 to 5 mg/kg selectively blocks the presynaptic mesolimbic D2 DA autoreceptors and releases DA which stimulates the postsynaptic mesolimbic D2 and D1 DA receptors and induces cage climbing behaviour. Buspirone, at 10, 20 and 40 mg/kg blocks the postsynaptic striatal and mesolimbic D2 and D1 DA receptors. Pretreatment with 1-tryptophan, dexfenfluramine and fluoxetine antagonized buspirone induced cage climbing behaviour and potentiated buspirone induced catalepsy. Pretreatment with trazodone, mianserin and p-chlorophenylalanine potentiated buspirone induced cage climbing behaviour and antagonized buspirone induced catalepsy. The results indicate that drugs which influence the activity of central serotonergic systems modulate the intensity of buspirone induced cage climbing behaviour and catalepsy.
Subject(s)
Buspirone/administration & dosage , Dopamine D2 Receptor Antagonists , Animals , Anti-Anxiety Agents/administration & dosage , Catalepsy/chemically induced , Dose-Response Relationship, Drug , Haloperidol/administration & dosage , Male , Mice , Serotonin Receptor Agonists/administration & dosage , Stereotyped Behavior/drug effects , Tryptophan/administration & dosageABSTRACT
Dextromethorphan, a noncompetitive blocker of N-methyl-D- aspartate (NMDA) type of glutamate receptor, at 7.5-75 mg/kg, ip did not induce oral stereotypies or catalepsy and did not antagonize apomorphine stereotypy in rats. These results indicate that dextromethorphan at 7.5-75 mg/kg does not stimulate or block postsynaptic striatal D2 and D1 dopamine (DA) receptors. Pretreatment with 15 and 30 mg/kg dextromethorphan potentiated dexamphetamine stereotypy and antagonised haloperidol catalepsy. Pretreatment with 45, 60 and 75 mg/kg dextromethorphan, which release 5-hydroxytryptamine (5-HT), however, antagonised dexamphetamine stereotypy and potentiated haloperidol catalepsy. Apomorphine stereotypy was not potentiated or antagonised by pretreatment with 7.5-75 mg/kg dextromethorphan. This respectively indicates that at 7.5-75 mg/kg dextromethorphan does not exert facilitatory or inhibitory effect at or beyond the postsynaptic striatal D2 and D1 DA receptors. The results are explained on the basis of dextromethorphan (15-75 mg/kg)-induced blockade of NMDA receptors in striatum and substantia nigra pars compacta. Dextromethorphan at 15 and 30 mg/kg, by blocking NMDA receptors, activates nigrostriatal dopaminergic neurons and thereby potentiates dexampetamine stereotypy and antagonizes haloperidol catalepsy. Dextromethorphan at 45, 60 and 75 mg/kg, by blocking NMDA receptors, releases 5-HT and through the released 5-HT exerts an inhibitory influence on the nigrostriatal dopaminergic neurons with resultant antagonism of dexampetamine stereotypy and potentiation of haloperidol catalepsy.
Subject(s)
Antitussive Agents/pharmacology , Catalepsy/chemically induced , Dextromethorphan/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Stereotyped Behavior/drug effects , Animals , Antitussive Agents/toxicity , Apomorphine/pharmacology , Behavior, Animal/drug effects , Dextroamphetamine/pharmacology , Dextromethorphan/toxicity , Dopamine/metabolism , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacokinetics , Dopamine Uptake Inhibitors/pharmacology , Haloperidol/toxicity , Male , Rats , Rats, Wistar , Receptors, Dopamine/drug effects , Receptors, Dopamine/metabolism , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitorsABSTRACT
Buspirone, a partial agonist of 5-hydroxytryptamine autoreceptors, selectively blocks presynaptic nigrostriatal D2 dopamine (DA) autoreceptors. At doses which antagonised action of apomorphine in biochemical presynaptic nigrostriatal D2 DA autoreceptor test systems buspirone neither induced catalepsy nor antagonised apomorphine-induced turning behaviour in rats indicating that at these doses buspirone does not block postsynaptic striatal D2 and D1 DA receptors. This study determines whether at high doses buspirone blocks postsynaptic striatal D2 and D1 DA receptors and provides behavioural evidence for selective blockade of presynaptic nigrostriatal D2 DA autoreceptors by smaller doses of buspirone. We investigated in rats whether buspirone induces catalepsy and effect of its pretreatment on DA agonist induced oral stereotypies and on cataleptic effect of haloperidol and small doses (0.05, 0.1 mg/kg, ip) of apomorphine. Buspirone at 1.25, 2.5, 5 mg/kg, ip neither induced catalepsy nor antagonised apomorphine stereotypy but did potentiate dexamphetamine stereotypy and antagonised cataleptic effect of haloperidol and small doses of apomorphine. Buspirone at 10, 20, 40 mg/kg, ip induced catalepsy and antagonised apomorphine and dexamphetamine stereotypies. Our results indicate that buspirone at 1.25, 2.5, 5 mg/kg blocks only presynaptic nigrostriatal D2 DA autoreceptors while at 10, 20, 40 mg/kg, it blocks postsynaptic striatal D2 and D1 DA receptors. Furthermore, buspirone at 1.25, 2.5, 5 mg/kg by selectively blocking presynaptic nigrostriatal D2 DA autoreceptors, increases synthesis of DA and makes more DA available for release by dexamphetamine and during haloperidol-induced compensatory 'feedback' increase of nigrostriatal DAergic neuronal activity and thus potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
Subject(s)
Buspirone/pharmacology , Catalepsy/chemically induced , Dopamine Antagonists/pharmacology , Stereotyped Behavior/drug effects , Animals , Apomorphine/pharmacology , Dextroamphetamine/pharmacology , Dopamine D2 Receptor Antagonists , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Rats , Rats, Wistar , Receptors, Dopamine D1/antagonists & inhibitors , Receptors, Dopamine D1/physiology , Receptors, Dopamine D2/physiologyABSTRACT
Dextromethorphan, a noncompetitive blocker of the N-methyl-D-aspartate (NMDA) type of glutamate receptor, at 45, 60 and 75 mg/kg, ip doses induced a behavioural syndrome characterised by reciprocal forepaw treading, lateral head-weaving, hind-limb abduction and flat body posture. Such type of behavioural syndrome is induced by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT) by directly stimulating the central postsynaptic 5-hydroxytryptamine (5-HT, serotonin) receptors of the 5-HT1A type. Pretreatment with buspirone (5, 10 mg/kg, ip) and l-propranolol (10, 20 mg/kg, ip) antagonised the behavioural syndrome induced by 8-OH-DPAT and dextromethorphan. Pretreatment with p-chlorophenylalanine (100 mg/kg/day x 4 days) antagonised the behavioural syndrome induced by dextromethorphan and dexfenfluramine but had no significant effect on 8-OH-DPAT induced behavioural syndrome. This indicates that dextromethorphan induces the behavioural syndrome by releasing 5-HT from serotonergic neurons with resultant activation of the postsynaptic 5-HT1A receptors by the released 5-HT. Pretreatment with fluoxetine (10 mg/kg, ip) significantly potentiated the behavioural syndrome induced by dextromethorphan and 5-hydroxytryptophan but significantly antagonised dexfenfluramine induced behavioural syndrome. This indicates that dextromethorphan releases 5-HT by a mechanism which differs from that of dexfenfluramine. Dextromethorphan may be releasing 5-HT by blocking the NMDA receptors and thereby counteracting the inhibitory influence of l-glutamate on 5-HT release.
Subject(s)
Behavior, Animal/drug effects , Central Nervous System/drug effects , Dextromethorphan/toxicity , 8-Hydroxy-2-(di-n-propylamino)tetralin/toxicity , Animals , Antitussive Agents/toxicity , Behavior, Animal/physiology , Buspirone/pharmacology , Central Nervous System/physiopathology , Dexfenfluramine/toxicity , Fluoxetine/pharmacology , Male , Propranolol/pharmacology , Rats , Rats, Wistar , Serotonin/physiology , Serotonin Receptor Agonists/toxicity , SyndromeABSTRACT
5-hydroxytryptamine (5-HT) inhibits the synthesis and release of dopamine (DA) from rat nigrostriatal DAergic neurons. Dexfenfluramine releases 5-HT from brain 5-HTergic neurons. The present study was undertaken to determine whether dexfenfluramine, through the released 5-HT, modulates the intensity of the behaviours dependent on the functional status of the nigrostriatal DAergic system. The effect of pretreatment with dexfenfluramine on dexamphetamine and apomorphine stereotypies of the oral movement variety and on catalepsy induced by haloperidol and small doses (0.05 and 0.1 mg/kg ip) of apomorphine was studied in rats. We also investigated whether dexfenfluramine induces catalepsy in rats. Dexfenfluramine at 2.5, 5 and 10 mg/kg ip did not induce catalepsy and did not antagonise apomorphine stereotypy. However, 1 h pretreatment with 5-HT releasing doses of dexfenfluramine ie 5 and 10 mg/kg ip, antagonized dexamphetamine stereotypy and potentiated catalepsy induced by haloperidol and small doses of apomorphine. Our results, that dexfenfluramine at 2.5, 5 and 10 mg/kg ip neither induced catalepsy nor antagonised apomorphine stereotypy, indicate that dexfenfluramine at these doses does not block the postsynaptic striatal D2 and D1 DA receptors. They also indicate that the 5-HT released by 5 and 10 mg/kg dexfenfluramine does not exert an inhibitory effect at or beyond the postsynaptic striatal D2 and D1 DA receptor sites. However, 5 and 10 mg/kg doses of dexfenfluramine, through the released 5-HT, inhibit the synthesis and release of DA from the nigrostriatal DAergic neurons and thus antagonise dexamphetamine stereotypy and potentiate catalepsy induced by haloperidol and small doses of apomorphine.
Subject(s)
Dexfenfluramine/pharmacology , Dopamine/metabolism , Stereotyped Behavior/drug effects , Animals , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Rats , Rats, Wistar , Stereotyped Behavior/physiologyABSTRACT
Amantadine, a dopamine agonist is reported to act by releasing dopamine from the dopaminergic nerve terminals as an anti-Parkinsonian drug. In the present behavioural study in the rat, molindone-induced catalepsy and ptosis, which are dopamine dependent-behaviors are reversed by amantadine. Amantadine has also revered molindone-induced inhibition of traction response in mice. Our study indicates that amantadine, like other DA agonists, e.g. amphetamine and apomorphine can antagonize or even reverse the neuroleptic induced dopaminergic behaviors.
Subject(s)
Amantadine/pharmacology , Behavior, Animal/drug effects , Catalepsy/prevention & control , Dopamine Agents/pharmacology , Animals , Blepharoptosis/etiology , Blepharoptosis/prevention & control , Catalepsy/chemically induced , Catalepsy/complications , Catalepsy/metabolism , Disease Models, Animal , Dopamine/metabolism , Drug Interactions , Male , Mice , Mice, Inbred Strains , Molindone , Probability , Rats , Rats, Inbred Strains , Reference Values , Species SpecificityABSTRACT
1. Radio-ligand binding study has demonstrated that flunarizine has a high affinity for the rat striatal D 2 dopamine (DA) receptors. 2. In the present behavioural study conducted in rats it was observed that flunarizine, unlike the postsynaptic striatal D 2 DA receptor agonist apomorphine, did not induce stereotyped behaviour (SB) in rats. This indicates that flunarizine does not act as an agonist at the postsynaptic striatal D 2 DA receptors. 3. Flunarizine however, like the postsynaptic striatal D 2 DA receptor antagonist haloperiodal, inhibited the conditioned avoidance response, induced catalepsy and antagonized the SB induced by the DA agonists apomorphine and methamphetamine. 4. Our findings indicate that flunarizine acts as a postsynaptic striatal D 2 DA receptor antagonist.
Subject(s)
Avoidance Learning/drug effects , Behavior, Animal/drug effects , Calcium Channel Blockers/pharmacology , Catalepsy/chemically induced , Dopamine/pharmacology , Flunarizine/pharmacology , Stereotyped Behavior/drug effects , Animals , Apomorphine/pharmacology , Corpus Striatum/drug effects , Dopamine D2 Receptor Antagonists , Drug Therapy, Combination , Injections, Intraperitoneal , Male , Methamphetamine/pharmacology , RatsABSTRACT
Abstract : Verapamil at 5, 10 and 20 mg/kg ip did not inhibit the conditioned avoidance response, neither induced catalepsy nor antagonised apomorphine stereotypy in rats indicating that these doses do not block the postsynaptic striatal D 2 and D 1 dopamine (DA) receptors. However, pretreatment with 10 and 20 mg/kg ip verapamil potentiated methamphetamine stereotypy and antagonised catalepsy induced by small doses (0.05 and 0.1 mg/kg ip) of apomorphine. Antagonism of small dose apomorphine-induced catalepsy suggests that at these doses verapamil blocks the presynaptic D2 DA autoreceptors. Further, pretreatment with 10 mg/kg verapamil antagonised, while pretreatment with 20 mg/kg potentiated haloperidol catalepsy. Potentiation of methamphetamine stereotypy by 10 and 20 mg/kg verapamil is explained on the basis of blockade of presynaptic D2 DA autoreceptors by these doses of verapamil and its reported DA neuronal uptake blocking activity. Antagonism of haloperidol catalepsy by 10 mg/kg verapamil is also explained on the basis of presynaptic D2 DA autoreceptor induced blockade by 10 mg/kg verapamil whereas potentiation of haloperidol catalepsy by 20 mg/kg verapamil is explained on the basis of its calcium channel blocking activity.
Subject(s)
Dopamine/physiology , Verapamil/pharmacology , Animals , Apomorphine/pharmacology , Avoidance Learning/drug effects , Catalepsy/chemically induced , Haloperidol/pharmacology , Male , Rats , Receptors, Dopamine D2/physiologyABSTRACT
Metoclopramide (5 to 40 mg/kg, i.p.) induces catalepsy and antagonised apomorphine induced cage climbing behaviour in mice. This further indicate its postsynaptic striatal and mesolimbic D 2 dopamine (DA) receptor blocking activity. Metoclopramide at 1.25 and 2.5 mg/kg, i.p. induced stereotyped cage climbing behaviour in mice. Pretreatment with haloperidol and alpha-methyl-p-tyrosine significantly antagonised metoclopramide (1.25 and 2.5 mg/kg)-induced stereotyped cage climbing behaviour. Metoclopramide at these doses induces stereotyped cage climbing behaviour by releasing DA from the mesolimbic dopaminergic neurons with resultant activation of the postsynaptic mesolimbic D 2 DA receptors by the released DA. DA releasing action of metoclopramide (1.25 and 2.5 mg/kg, i.p.) and the subsequent induction of the stereotyped cage climbing behaviour by these doses of metoclopramide is explained on the basis of selective blockade of the presynaptic D 2 DA autoreceptors by these doses of metoclopramide.
Subject(s)
Antiemetics/pharmacology , Central Nervous System/drug effects , Dopamine Antagonists/pharmacology , Metoclopramide/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Male , MiceABSTRACT
Pentazocine, a kappa opioid receptor agonist, induced catalepsy in mice suggesting thereby that it might possess postsynaptic striatal D 2 dopamine (DA) receptor blocking activity. However, our other findings, that pentazocine pretreatment did not antagonise the cage climbing behaviour induced by the directly acting DA agonist apomorphine in mice and actually potentiated the stereotyped behaviour induced by the indirectly acting DA agonist methamphetamine in mice, indicate that pentazocine does not possess postsynaptic striatal and mesolimbic D 2 DA receptor blocking activity. Pretreatment with naloxone, an antagonist of opioid receptors, antagonised pentazocine-induced catalepsy. This suggests the possible involvement of opioid mechanisms in the induction of catalepsy by pentazocine in mice.
Subject(s)
Dopamine Antagonists/pharmacology , Locomotion/drug effects , Pentazocine/pharmacology , Receptors, Opioid, kappa/agonists , Stereotyped Behavior/drug effects , Animals , Male , MiceABSTRACT
Racemate pentazocine was found to induce stereotyped behaviour (SB) in rats. Pretreatment with haloperidol and alpha-methyl-p-tyrosine significantly antagonised dl-pentazocine induced SB. This indicates that dl-pentazocine induces SB by releasing dopamine (DA) from the nigrostriatal and mesolimbic dopaminergic neurones with resultant activation of the postsynaptic striatal and mesolimbic D2 DA receptors by the released DA. However, pretreatment with naloxone failed to significantly modify dl-pentazocine induced SB indicating thereby that opioid mechanisms are not involved in the DA releasing action of dl-pentazocine. Our findings are explained on the basis of recent reports that the d-isomer of pentazocine releases DA by stimulating sigma receptors located on the nigrostriatal and mesolimbic dopaminergic neurones.
Subject(s)
Analgesics, Opioid/pharmacology , Dopamine/physiology , Pentazocine/pharmacology , Stereotyped Behavior/drug effects , Animals , Male , Methyltyrosines/pharmacology , Naloxone/pharmacology , Rats , Stereoisomerism , alpha-MethyltyrosineSubject(s)
Antidepressive Agents/pharmacology , Catalepsy/prevention & control , Haloperidol , Morphine , Propiophenones/pharmacology , Animals , Bupropion , Female , Male , RatsABSTRACT
In the present study we have investigated the effect of yohimbine on dopamine-dependent behaviours in rats and mice. Yohimbine (1.25 to 10 mg/kg, ip) failed to block the conditioned avoidance response in rats, to inhibit the traction response in mice and to induce catalepsy in rats and mice. Pretreatment with yohimbine (1.25 to 10 mg/kg, ip) had no significant effect on apomorphine stereotypy in rats and apomorphine induced cage climbing behaviour in mice. However, pretreatment with yohimbine (1.25 to 10 mg/kg. ip) significantly increased the intensity of methamphetamine stereotypy and antagonised haloperidol catalepsy in rats. Our findings indicate that yohimbine does not possess postsynaptic striatal and mesolimbic D-2 dopamine receptor blocking activity.
Subject(s)
Behavior, Animal/drug effects , Dopamine/physiology , Yohimbine/pharmacology , Animals , Apomorphine/pharmacology , Avoidance Learning/drug effects , Behavior, Animal/physiology , Catalepsy/chemically induced , Haloperidol/pharmacology , Male , Methamphetamine/pharmacology , Mice , Psychomotor Performance/drug effects , Rats , Stereotyped Behavior/drug effectsABSTRACT
Ergometrine (2.5-80 mg/kg IP) induced head twitches in mice. Pretreatment with cyproheptadine (1.5 and 3 mg/kg), methysergide (5 and 10 mg/kg) and (-)-propranolol (2.5 and 5 mg/kg) significantly decreased the number of head twitches induced by ergometrine. Pretreatment with p-chlorophenylalanine (100 mg/kg/day X 4 days) and clomipramine (5 and 10 mg/kg) significantly decreased the number of head twitches induced by fenfluramine (10 mg/kg) and p-chloramphetamine (5 mg/kg) but had no significant effect on the number of head twitches induced by ergometrine. The results indicate that ergometrine induces head twitches in mice by directly stimulating central 5-hydroxytryptamine receptors.
Subject(s)
Ergonovine/pharmacology , Receptors, Serotonin/drug effects , Stereotyped Behavior/drug effects , Animals , Clomipramine/pharmacology , Cyproheptadine/pharmacology , Dose-Response Relationship, Drug , Fenclonine/pharmacology , Fenfluramine/pharmacology , Male , Methysergide/pharmacology , Mice , Propranolol/pharmacology , Time Factors , p-Chloroamphetamine/pharmacologyABSTRACT
Bromocriptine (5-30 mg/kg, ip), 2 hr after administration, induced cage climbing behaviour in mice. Pretreatment with haloperidol, an antagonist of both D-1 and D-2 dopamine receptors, metoclopramide and molindone, the selective D-2 dopamine receptor antagonists, effectively antagonised bromocriptine-induced climbing behaviour. The results indicate that bromocriptine most probably induces climbing behaviour in mice by stimulating the postsynaptic striatal D-2 dopamine receptors.
Subject(s)
Behavior, Animal/drug effects , Bromocriptine/pharmacology , Motor Activity/drug effects , Animals , Bromocriptine/antagonists & inhibitors , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Metoclopramide/pharmacology , Mice , Molindone/pharmacology , Receptors, Dopamine/drug effects , Receptors, Dopamine D2ABSTRACT
Pretreatment with the DAi receptor antagonist ergometrine (10, 20 mg kg-1 i.p.) significantly potentiated methamphetamine stereotypy and facilitated the induction of biting, gnawing or licking behaviour by amantadine. However, ergometrine (5-20 mg kg-1) did not significantly influence the stereotyped behaviour induced by the DAe receptor agonist apomorphine. The results suggest that the DAi antagonist ergometrine is effective in modifying the behaviours induced by methamphetamine and amantadine, agents which through released DA simultaneously activate both DAe and DAi receptors, but fails to modify the stereotyped behaviour induced by apomorphine which specifically activates only DAe receptors. However, the possibility that ergometrine might have potentiated methamphetamine stereotypy and facilitated the induction of biting, gnawing or licking behaviour by amantadine through modulation of the activity of the central noradrenergic and 5-hydroxytryptaminergic systems, which are reported to influence DA-mediated behaviours, also needs to be considered.
Subject(s)
Apomorphine/pharmacology , Ergonovine/pharmacology , Methamphetamine/pharmacology , Stereotyped Behavior/drug effects , Amantadine/pharmacology , Animals , Drug Synergism , Guinea Pigs , Humans , Male , Receptors, Dopamine/drug effects , Time FactorsABSTRACT
Pretreatment with fenfluramine (5 and 10 mg/kg, ip) in doses which induced head twitches was found to antagonize apomorphine-induced cage climbing behaviour and methamphetamine stereotypy in mice. Since fenfluramine (5 and 10 mg/kg) did not induce catalepsy it indicates that fenfluramine lacks postsynaptic striatal and mesolimbic dopamine receptor blocking activity and it is possible that the fenfluramine-induced enhancement of central 5-hydroxytryptamine neuronal transmission may be responsible for its antagonistic effect on apomorphine-induced climbing behaviour and methamphetamine stereotypy.
Subject(s)
Apomorphine/antagonists & inhibitors , Fenfluramine/pharmacology , Methamphetamine/antagonists & inhibitors , Stereotyped Behavior/drug effects , Animals , Catalepsy/chemically induced , Humans , Male , MiceSubject(s)
Amodiaquine/pharmacology , Catalepsy/chemically induced , Clonidine/pharmacology , Morphine/pharmacology , Animals , Drug Synergism , Humans , Male , MiceABSTRACT
24 h pretreatment with molindone enhanced the behavioural effects of L-dopa and 5-HTP, precursors of biogenic amines (catecholamines and 5-HT respectively) preferentially deaminated by MAO-A, confirming that a metabolite of molindone inhibits MAO-A. 24 h pretreatment with molindone enhanced the behavioural effects of tryptamine and antagonized reserpine-induced ptosis, and in molindone-pretreated rats L-tryptophan induced behavioural effects, probably because of the MAO-A inhibitory activity exerted by a metabolite of molindone. Since 24 h pretreatment with molindone, unlike 30 min pretreatment with clomipramine, failed to antagonize fenfluramine and p-chloramphetamine-induced behavioural syndromes, it suggests that molindone and/or its metabolites most probably do not exert 5-HT neuronal uptake blocking activity and the potentiation of 5-HTP-induced behavioural syndrome is due to a metabolite's MAO-A inhibitory activity. As 2 h pretreatment with molindone induced catalepsy and antagonized apomorphine-induced climbing behaviour in mice and stereotypy in rats, while 24 h pretreatment failed to induce catalepsy and to antagonize apomorphine-induced behaviour, it appears that, at 24 h, the tissue levels of molindone are inadequate to block postsynaptic striatal and mesolimbic DA receptors and that, though a metabolite of molindone is biologically active so far as inhibition of MAO-A is concerned, the metabolites are devoid of neuroleptic activity. Further, since 2 h pretreatment with molindone failed to enhance the behavioural effects of L-dopa, it suggests that at 2 h the degree of MAO-A inhibition induced by molindone and/or the metabolite is not sufficient to counteract the neuroleptic activity of the parent compound.
Subject(s)
Behavior, Animal/drug effects , Indoles/pharmacology , Molindone/pharmacology , Monoamine Oxidase Inhibitors , 5-Hydroxytryptophan/pharmacology , Animals , Apomorphine/pharmacology , Blepharoptosis/chemically induced , Catalepsy/chemically induced , Fenclonine/pharmacology , Fenfluramine/pharmacology , Humans , Levodopa/pharmacology , Male , Mice , Rats , Reserpine/pharmacology , Stereotyped Behavior/drug effects , Tryptamines/pharmacology , Tryptophan/pharmacology , p-Chloroamphetamine/pharmacologyABSTRACT
Pretreatment with the opiate antagonist naloxone, at 1.25-5 mg/kg, increased the intensity of methamphetamine stereotypy, had no effect (over a range of 0.3125-5 mg/kg) on apomorphine stereotypy, and antagonized haloperidol catalepsy in rats at 1.25-5 mg/kg. It is suggested that naloxone, by blocking the opiate receptors located on the nigro-striatal and mesolimbic dopamine (DA) nerve terminals, releases the DA systems from endogenous inhibition, presumably caused by endogenous opiate systems, and thereby potentiates methamphetamine stereotypy and antagonizes haloperidol catalepsy. However, the possibility that naloxone might have affected methamphetamine stereotypy and haloperidol catalepsy by modulating the activity of the central noradrenergic and GABAergic systems, which are reported to influence dopaminergically mediated behaviours, also needs to be considered.